Status and phase
Conditions
Treatments
About
A phase III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
241 participants in 1 patient group
Loading...
Central trial contact
Teresa Prat, Dr.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal